Summary Stage 2018: Cervix
Summary Stage 2018
Notes
**Cervix**
8000-8700, 8710-8803, 8805, 8810-8814, 8816-8858, 8860-8900, 8902-8910, 8921-8941, 8951-8976, 8980-8990, 8992-9016, 9030-9043, 9045-9111, 9121-9132, 9135-9138, 9141-9175, 9181-9221, 9230, 9240-9365, 9370-9580, 9582
C530-C531, C538-C539
C530 Endocervix
C531 Exocervix
C538 Overlapping lesion of cervix
C539 Cervix uteri
**Note 1:** The following sources were used in the development of this chapter
* SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf)
* SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/)
* Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx
* Chapter 52 *Cervix Uteri*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois.
* Cervix Uteri, from the AJCC Cancer Staging System Version 9 (2020). Used with permission of the American College of Surgeons, Chicago, Illinois
* Chapter 54 *Corpus Uteri-Sarcoma,* in the AJCC Cancer Staging Manual, Eight Edition (2017) published by Spring International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois
**Note 2:** See the following chapters for the listed histologies
* 8815, 8859, 8901, 8912, 8920, 8950, 9120, 9133, 9180, 9222, 9366-9368, 9581: *Soft Tissue*
* 9140: *Kaposi Sarcoma*
* 9700-9701: *Mycosis Fungoides*
**Note 3:** Isolated tumor cells (ITCs) are defined as single tumor cells or small clusters not greater than 0.2 mm, usually detected by immunohistochemical (IHC) or molecular methods. ITCs do not usually show evidence of malignant activity (e.g., proliferation or stromal reaction).
* Lymph nodes with ITCs only are **not** counted as positive nodes for Summary Stage
**Note 4:** Para-aortic nodes are now regional instead of distant.
(1) Fritz AG, Ries LAG (eds). **SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998)**, National Cancer Institute, NIH Pub. No. 98-2313, Bethesda, MD, 1998
(2) Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA (eds.). **SEER Summary Staging Manual-2000: Codes and Coding Instructions**, National Cancer Institute, NIH Pub. No. 01-4969, Bethesda, MD, 2001.
(3) Collaborative Stage Work Group of the American Joint Committee on Cancer. **Collaborative Stage Data Collection System User Documentation and Coding Instructions, version 02.05.** American Joint Committee on Cancer (Chicago, IL)
(4) Gress, D.M., Edge, S.B., Gershenwald, J.E., et al. **Principles of Cancer Staging**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017
(5) **Introduction to Female Reproductive Organs**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017
(6) Erickson, B.A., Olawaiye, A.B., Mutch, D.G., et al. **Cervix Uteri**. In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017
(7) Dizon, D.S., Olawaiye, A.B., Mutch, D.G., et al. **Corpus Uteri - Sarcoma.** In: Amin, M.B., Edge, S.B., Greene, F.L., et al. (Eds.) AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017